Clinical trials: Polymyalgia Rheumatica
Giant Cell Arteritis
A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis
The primary purpose of this study is to evaluate the efficacy of guselkumab compared to placebo, in combination with a 26-week glucocorticoid (GC) taper regimen, in adult participants with new-onset or relapsing giant cell…
- Trial name
- THEIA (NCT04633447)
- Testing
- Guselkumab
- Where
- 30 sites in United States, Belgium and 7 more
- Volunteers
- 53 people
- Sponsor
- Janssen Research & Development, LLC
Polymyalgia Rheumatica
Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica
Primary Objective: To evaluate the efficacy of KEVZARA (sarilumab) in participants with polymyalgia rheumatica (PMR) as assessed by the proportion of participants with sustained remission for sarilumab with a shorter…
- Trial name
- NCT03600818
- Testing
- Sarilumab SAR153191 (REGN88), Prednisone
- Where
- 84 sites in United States, Argentina and 15 more
- Volunteers
- 118 people
- Sponsor
- Sanofi